Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that it has received Drug Registration Certificates (Certificate Nos. 2026S03571 and 2026S03572) from China’s National Medical Products Administration (NMPA) for Cefuroxime Sodium for Injection, approving the product for registration. The drug was reviewed under the Chemical Drug Class 4 (generic) pathway, having been found to meet the requirements of the Drug Administration Law of the People’s Republic of China and related regulations.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Regulatory Action | Drug Registration Certificate issued; registration approved |
| Product | Cefuroxime Sodium for Injection |
| Dosage Form | Injection (powder for injection) |
| Specifications | 0.75 g and 1.5 g (calculated as C₁₆H₁₆N₄O₈S) |
| Approval Numbers | National Drug Approval Numbers: H20266084, H20266085 |
| Drug Standard | YBH28282026 |
| Registration Class | Chemical Drug Class 4 (generic) |
| Manufacturer | Shandong Lukang Pharmaceutical Co., Ltd. |
| Certificate Numbers | 2026S03571, 2026S03572 |
Drug Profile & Mechanism of Action
- Molecule: Cefuroxime, a bactericidal cephalosporin antibiotic (second generation).
- Enzyme Stability: Resistant to most β‑lactamases, supporting activity against enzyme‑producing strains.
- Spectrum: Effective against a broad range of Gram‑positive and Gram‑negative bacteria, a profile that has made cefuroxime a mainstay of parenteral antibacterial therapy.
- Development Pathway: Approved as a Class 4 generic, indicating consistency with the reference listed drug in quality and efficacy.
- R&D Investment: The company has invested approximately RMB 2.79 million (≈ US$390,000, unaudited) in the development of Cefuroxime Sodium for Injection as of the announcement date.
Market Landscape
| Metric | Detail |
|---|---|
| Competitive Field | 46 domestic companies have passed consistency evaluation or been approved under the new generic registration classification |
| 2025 China Sales | RMB 2.645 billion (≈ US$370 million) – PDB data |
| Q1 2026 China Sales | RMB 517 million (≈ US$72 million) – PDB data |
Market Impact & Outlook
- Established, Sizeable Market: With RMB 2.645 billion in 2025 domestic sales and RMB 517 million in the first quarter of 2026, Cefuroxime Sodium for Injection remains a high‑volume parenteral antibiotic franchise in China.
- Crowded Generic Field: The 46 approved or consistency‑evaluated competitors mean Lukang enters a market where price competition and volume‑based procurement (VBP) dynamics will largely determine share capture.
- Portfolio Broadening: The new certificates extend Lukang’s anti‑infective portfolio with two commercial specifications (0.75 g and 1.5 g), supporting hospital tender eligibility across dosing needs.
- Low Development Cost, Fast Payback Potential: Cumulative R&D spend of approximately RMB 2.79 million is modest relative to the market size, though commercial returns will depend on procurement pricing and channel execution.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Cefuroxime Sodium for Injection, including commercialization expectations, market share potential, and procurement participation following NMPA registration approval. Actual results may differ due to risks including competitive pricing, volume‑based procurement outcomes, hospital access, and market demand. Sales data cited are from PDB as disclosed in the company’s announcement; R&D investment figures are unaudited.-Fineline Info & Tech
